### Table of Contents

**March 1, 2015 • Volume 75 • Number 5**

#### Breaking Advances

824 ERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors  
Loredana Cifaldi, Paolo Romania, Michela Falco, Silvia Lorenzi, Raffaella Meazza, Stefania Petroni, Marco Andreani, Daniela Pende, Franco Locatelli, and Doriana Pruci

#### Reviews

781 Highlights from Recent Cancer Literature

783 Signaling-Mediated Regulation of MicroRNA Processing  
Jia Shen and Mien-Chie Hung

792 Fearful Symmetry: Subversion of Asymmetric Division in Cancer Development and Progression  
Jeevisha Bajaj, Bryan Zimdahl, and Tannishtha Reya

798 The Emerging Protumor Role of γδ T Lymphocytes: Implications for Cancer Immunotherapy  
Margarida Rei, Daniel J. Pennington, and Bruno Silva-Santos

#### Perspectives

803 Breast Cancer Prevention: Lessons to be Learned from Mechanisms of Early Pregnancy–Mediated Breast Cancer Protection  
Fabienne Meier-Abt, Mohamed Bentires-Alj, and Christoph Rochlitz

808 Redundancy: A Critical Obstacle to Improving Cancer Therapy  
Orit Lavi

#### Microenvironment and Immunology

813 Akt–Girdin Signaling in Cancer-Associated Fibroblasts Contributes to Tumor Progression  
Yumiko Yamamura, Naoya Asai, Atsushi Enomoto, Takuya Kato, Shinji Mii, Yuji Kondo, Kaori Ushida, Koaru Niimi, Nobuyuki Tsunoda, Masato Nagino, Shu Ichihara, Koichi Furukawa, Kengo Maeda, Toyoaki Murohara, and Masahide Takahashi

824 ERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors  
Loredana Cifaldi, Paolo Romania, Michela Falco, Silvia Lorenzi, Raffaella Meazza, Stefania Petroni, Marco Andreani, Daniela Pende, Franco Locatelli, and Doriana Pruci

835 Genetic and Pharmacological Inactivation of the Purinergic P2RX7 Receptor Dampens Inflammation but Increases Tumor Incidence in a Mouse Model of Colitis-Associated Cancer  
Paul Hofman, Julien Cherfils-Vicini, Marie Bazin, Marius Ilie, Thierry Juhel, Xavier Hébenerne, Eric Gilson, Annie Schmid-Alliana, Olivier Boyer, Sahil Adrouch, and Valérie Vouret-Craviari

835 Genomic and Pharmacological Inactivation of the Purinergic P2RX7 Receptor Dampens Inflammation but Increases Tumor Incidence in a Mouse Model of Colitis-Associated Cancer  
Paul Hofman, Julien Cherfils-Vicini, Marie Bazin, Marius Ilie, Thierry Juhel, Xavier Hébenerne, Eric Gilson, Annie Schmid-Alliana, Olivier Boyer, Sahil Adrouch, and Valérie Vouret-Craviari

846 Long Noncoding RNA HULC Modulates Abnormal Lipid Metabolism in Hepatoma Cells through an miR-9–Mediated RXRA Signaling Pathway  
Ming Cui, Zelin Xiao, Yue Wang, Minying Zheng, Tianqiang Song, Xiaoli Cai, Baodi Sun, Lihong Ye, and Xiaodong Zhang

#### Molecular and Cellular Pathobiology

846 Long Noncoding RNA HULC Modulates Abnormal Lipid Metabolism in Hepatoma Cells through an miR-9–Mediated RXRA Signaling Pathway  
Ming Cui, Zelin Xiao, Yue Wang, Minying Zheng, Tianqiang Song, Xiaoli Cai, Baodi Sun, Lihong Ye, and Xiaodong Zhang

**v**
Single-Strand DNA-Binding Protein SSB1 Facilitates TERT Recruitment to Telomeres and Maintains Telomere G-Overhangs
Raj K. Pandita, Tracy T. Chow, Durga Udayakumar, Amanda L. Bain, Liza Cubeddu, Clayton R. Hunt, Wei Shi, Nobuo Horikoshi, Yong Zhao, Woodring E. Wright, Kum Kum Khanna, Jerry W. Shay, and Tej K. Pandita

Précis: These findings offer an explanation for how telomerase is recruited to telomeres, a critical step in maintaining telomere ends and cell viability in all cancer cells.

A Central Role for Heme Iron in Colon Carcinogenesis Associated with Red Meat Intake

Précis: Elevated risk of colon cancer associated with red meat consumption is linked to heme iron, which may initiate carcinogenesis by enabling lipid peroxidation, providing a possible etiologic basis to understand this connection.

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance
Nathalie Javidi-Sharifi, Elie Traer, Jacqueline Martinez, Anu Gupta, Takehiro Taguchi, Jennifer Dunlap, Michael C. Heinrich, Christopher L. Corless, Brian P. Rubin, Brian J. Druker, and Jeffrey W. Tyner

Précis: These findings provide a mechanistic rationale for use of existing FGFR inhibitors and multikinase inhibitors that target FGFR3 as strategies to improve treatment of gastrointestinal stromal tumors that exhibit resistance to imatinib mesylate, with immediate implications for clinical evaluation.
ABOUT THE COVER

The high concentration of extracellular ATP in inflammatory lesions activates the purinergic P2RX7 receptor, which is expressed on immune and nonimmune cells of the gastrointestinal tract. The P2RX7 receptor participates in the initiation as well as the regulation of the inflammatory response and consequently can favor colon carcinogenesis. Using both genetic and pharmacological models of P2RX7 inactivation, we found that P2RX7 acted at an early stage to suppress the development of colitis-associated cancer. For details, see the article by Hofman and colleagues on page 835.